7 hrs ago | PhillyBurbs.com
FDA clears Eli Lilly's blood thinner Effient
The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.
11 hrs ago | Pharmaceutical Processing
Lilly Cancer Drug Gets New Indication in Europe
Drugmaker Eli Lilly and Co. said Monday that European regulators have approved its cancer treatment Alimta for a new use against certain types of lung cancer.
After Hours: Alkermes, Amylin, Ruby Tuesday gain in late trade
Federal regulatory acceptance of a new drug application from Amylin Pharmaceuticals Inc.
Once-a-week diabetes drug advances
Drug makers Eli Lilly and Co. , Amylin Pharmaceuticals Inc. , and Alkermes Inc. said yesterday the Food and Drug Administration has accepted their application for the once-a-week diabetes drug exenatide.
Lilly Receives Fourth FDA Approval For ALIMTA(R) - First Chemotherapy ...
Lilly Receives Fourth FDA Approval For ALIMTA - First Chemotherapy Approved As Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer Eli Lilly and Company announced it received a fourth approval from the U.S. Food and Drug Administration for ALIMTA .
Elderly patients boost sales of dangerous antipsychotics
Bill Wiggins believes a powerful antipsychotic medication helped save his wife, Kathye.
Eli Lilly receives fourth FDA approval for ALIMTA
The latest approval is for ALIMTA as a maintenance therapy for locally advanced or metastatic non-small cell lung cancer , specifically for patients with a nonsquamous histology whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
Delaware settles with Eli Lilly
The Delaware Department of Justice announced it has reached a proposed settlement with Eli Lilly and Co.
"Brave" post-Lehman M&A rewarded by market -study
Although firms who made purchases worth $100 million or more suffered an average 25.5 percent fall in their stock price, they outperformed the wider market by 6.3 percentage points, the Towers Perrin/Cass Business School research found.
Carlsbad's Isis entering a new phase
Irma Sotelo-New, a scientist at Isis, worked near a condensing unit in the lab. - Isis Pharmaceuticals is a two-decade-old biotech company in Carlsbad that is on the verge of profitability.
Lilly: No July decision on Tippecanoe Labs
SHADELAND Officials with Eli Lilly and Co. on Tuesday informed employees at Tippecanoe Laboratories that a decision on the future of the facility won't be made by the end of July.
Lilly's Erbitux Cancer Drug Not Worth Its High Price, U.S. Scientists Say
Eli Lilly & Co.a s tumor-fighter Erbitux doesna t prolong lung cancer patientsa lives enough to justify its $80,000 cost, U.S. scientists said in commentary published today.
The Boulder County Business Report
Level 3 expands ImClone contract
Yes No BCBR Article Level 3 expands ImClone contract By Business Report Staff June 29, 2009 -- BROOMFIELD - Level 3 Communications Inc.
A front-row seat for the health-care debate
Bart Peterson didn't know when he sat next to Eli Lilly's John Lechleiter in March that he would be working for the chief executive in June.
U.S. Stocks Drop as Savings Rate Hits 15-Year High
U.S. stocks fell as the highest American savings rate in 15 years spurred concern that spending will slow, while falling oil drove down energy producers.
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
UTEK Corporation , a leading innovation services company, and The wRatings Corporation, an independent stock research firm, announced today the results of their annual Most Competitive Companies in Health Care Study.
Harvard-Trained, Eli Lilly and Company Researcher Joins Saint...
Jun 25, 2009 - Saint Joseph's Translational Research Institute , the research division of Saint Joseph's Health System, announced today that Jai Pal Singh, Ph.D., will join SJTRI as chief scientific officer.
An index measuring the expectations of 95 CEOs from among the nation's largest companies showed an improved outlook from last quarter's record low, but many still expect declines in sales, jobs and capital spending.
Antitrust query into Merck acquisition may prompt more deals
An antitrust inquiry into Merck & Co.'s planned purchase of Schering-Plough Corp.
Obama, drugmakers forge $80B discount deal
President Barack Obama today welcomed the pharmaceutical industry's agreement to help close a gap in Medicare's drug coverage, calling the pact a step forward in the push for an overhaul of the nation's health care system.